Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Fin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MH
10. DLMAF

Go back to Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Fin

Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company

May 5, 2020 1:56 PM EDT

Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.

... More

Akebia Therapeutics (AKBA) Tops Q1 EPS by 15c

May 5, 2020 7:43 AM EDT

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

... More